Y-mabs therapeutics, inc. (YMAB)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17
OPERATING EXPENSES
Research and development

18,622

16,835

19,660

14,494

12,511

11,072

8,731

8,293

6,204

3,076

General and administrative

8,125

6,931

4,699

4,140

3,742

3,037

2,684

1,965

1,275

766

Total operating expenses

26,747

23,758

24,359

18,634

16,253

14,078

11,415

10,258

7,479

3,842

Loss from operations

-26,747

-23,758

-24,359

-18,634

-16,253

-14,078

-11,415

-10,258

-7,479

-3,842

OTHER INCOME, NET
Interest and other income, net

568

622

437

598

319

18

-11

-47

-4

15

NET LOSS

-26,179

-23,136

-23,922

-18,036

-15,934

-14,060

-11,426

-10,305

-7,483

-3,827

Other comprehensive income
Foreign currency translation

25

-81

134

-66

56

55

39

78

3

-53

COMPREHENSIVE LOSS

-26,154

-23,217

-23,788

-18,102

-15,878

-14,005

-11,387

-10,227

-7,480

-3,880

Net loss per share attributable to common stockholders, basic and diluted

-0.66

-0.60

-0.70

-0.53

-0.47

-0.41

-0.42

-0.39

-0.28

-0.21

Weighted average common shares outstanding, basic and diluted

39,753

37,974

34,371

34,193

34,193

34,259

27,330

26,749

26,749

17,945